Neteo Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule inhibitors targeting the NLRP3 inflammasome for the treatment of neurodegenerative diseases, particularly Parkinson's disease. The company was founded with a mission to address neuroinflammation, a key driver of neurodegeneration that contributes to dopaminergic neuron loss in the substantia nigra.
| Attribute | Value |
|---|---|
| Founded | 2019 |
| Headquarters | Boston, Massachusetts, USA |
| CEO | Dr. Sarah Chen |
| Funding | Series B ($45M, 2023) |
| Focus | NLRP3 inflammasome inhibitors |
| Stage | Preclinical/Phase 1 |
Neteo's platform focuses on developing small molecule inhibitors that target the NACHT domain of NLRP3, preventing inflammasome assembly and subsequent activation of caspase-1 and release of pro-inflammatory cytokines IL-1β and IL-18. The company's approach is distinct in its focus on brain-penetrant molecules designed specifically for CNS applications.
The NLRP3 inflammasome plays a critical role in Parkinson's disease pathology:
Neteo's inhibitors block this pathway at the NLRP3 oligomerization step, preventing the downstream inflammatory cascade that drives disease progression.
| Drug | Mechanism | Development Stage | Status |
|---|---|---|---|
| NT-001 | NLRP3 direct inhibitor | Preclinical | IND-enabling |
| NT-002 | NLRP3/BTK dual inhibitor | Discovery | Lead optimization |
NT-001 is Neteo's lead NLRP3 inhibitor program for Parkinson's disease. Key features:
Preclinical data in the MPTP mouse model of PD showed:
NT-002 is a dual-action inhibitor targeting both NLRP3 and BTK (Bruton's tyrosine kinase). This approach addresses:
The dual mechanism may provide enhanced neuroprotection compared to single-target approaches.
Neteo has assembled a scientific advisory board with expertise in neuroinflammation and Parkinson's disease:
The Parkinson's disease market represents a significant opportunity for disease-modifying therapies:
| Parameter | Value |
|---|---|
| Global PD patients | ~10 million |
| Addressable market | $5-10B annually |
| Unmet need | No disease-modifying therapies approved |
| Competition | Dapansutrile (Olacteant), MCC950 (academic), DFV890 (Novartis) |
| Company | Drug | Stage | Advantage |
|---|---|---|---|
| Olacteant | Dapansutrile | Phase 2 | Clinical data available |
| NodThera | NT-0796 | Phase 1/2 | Brain-penetrant |
| Novartis | DFV890 | Phase 1 | Big pharma resources |
| Neteo | NT-001 | Preclinical | Dual-target approach |
| Ventus | VTS-101 | Discovery | Novel chemistry |